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Abstract
Cardiac lipotoxicity may induce cardiomyocyte apoptosis, eventually leading to myocardial
dysfunction and heart failure. This study investigated whether and how junctophilin-2 (JPH2)
plays a role in palmitate-induced apoptosis in cardiomyocytes. Here, we found palmitate
incubation reduced JPH2 protein levels, increased cytosolic Ca2+ and induced apoptosis in
cardiomyocytes. JPH2 over-expression prevented the increased cytosolic Ca2+ and apoptosis
in palmitate-stimulated cardiomyocytes. JPH2 over-expression also attenuated palmitateinduced CCAAT-enhancer-binding protein homologous protein (CHOP) expression and
CHOP deletion alleviated palmitate-induced apoptosis. Furthermore, blocking Ca2+ release
from ryanodine receptor-2 (RyR2) prevented palmitate-stimulated CHOP induction and
apoptosis. Additionally, JPH2 silencing elevated cytosolic Ca2+, induced CHOP expression
and apoptosis in cardiomyocytes; these effects of JPH2 silencing were inhibited by blocking
Ca2+ release from RyR2. In summary, we demonstrate that JPH2 attenuates palmitate-induced
apoptosis by reducing Ca2+ release from RyR2 and preventing CHOP expression in
cardiomyocytes. Thus, targeting JPH2 may represent a new therapeutic strategy to treat cardiac
lipotoxicity.

Keywords: Cardiomyocyte; Junctophilin-2; Palmitate; Apoptosis; Ca2+; CHOP;
Ryanodine receptor-2; Cardiac lipotoxicity.
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Summary for Lay Audience
The heart has both the greatest caloric needs and the most robust consumption of fatty acids
of the human organs. Under certain abnormal or disease conditions, heart muscle cells get
more fatty acids than they need and thus, the heart accumulates lipids. Excess lipids can
directly damage heart muscle cell structures, resulting in the heart not working properly, a
condition described as "cardiac lipotoxicity". Two human metabolic disorders are caused by
excess lipid accumulation in heart muscle cells: obesity-related heart muscle disease in
association with sudden heart death, and diabetic heart disease. The outcomes of cardiac
lipotoxicity include severe heart impairment leading to death or needing replacement of the
heart. Since type-2 diabetes and obesity are very common, cardiac lipotoxicity represents a
major public health concern. However, effective treatments are limited for patients, which
represents a major gap in patient care. Thus, further researches are urgently needed to better
understand this disease, identify new targets for treatment and develop effective treatment
modalities.
The objective of this study was to understand how a protein called "junctophilin-2" is
involved in cardiac lipotoxicity. Since the levels of this junctophilin-2 protein are reduced
in heart muscle cells during lipotoxicity, we examined whether addition of junctophilin-2
reduces heart muscle cell death caused by palmitate, a toxic lipid that has been widely
applied in the study of cardiac lipotoxicity. It is well known that junctophilin-2 is important in
maintaining a structure within cells which delivers ions (e.g. calcium) signals to force-generating
fibers in heart muscle cells, leading to contraction. We examined how junctophilin-2
normalizes calcium signals and inhibits the occurrence of a condition called "endoplasmic
reticulum stress", which causes heart muscle cell death under over-supply of palmitate. Thus,
this study will identify new targets for treatment.
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Chapter 1

1

Introduction

1.1

Cardiac lipotoxicity

Fatty acids (FAs) are the primary lipids used by the heart for energy production. The heart
balances uptake, oxidation and metabolism of FAs to maintain ATP production, lipid
signaling and membrane biosynthesis (1). Diabetes and obesity are prevalent in western
countries. In both conditions, cardiomyocytes take up excessive fatty acids which may alter
the structures of cells and activate downstream pathways, leading to cardiomyocyte
apoptotic cell death followed by myocardial dysfunction, a condition described as cardiac
lipotoxicity (2). This will eventually lead to adverse myocardial remodeling and heart
failure (3). However, it remains incompletely understood how the excessive lipids cause
cardiac dysfunction and heart failure.
The healthy adult heart acquires 60–80% of its energy requirements by mitochondrial βoxidation of fatty acids and 20–30% of its energy requirements from glucose. In addition,
ketone bodies, lactate and amino acids are also utilized for energy production (4, 5).
Normally, the origin of fatty acids supplied to the heart is either plasma fatty acids bound
to albumin or fatty acids contained within chylomicron- or very-low density lipoprotein
(VLDL)-triacylglycerol (TAG). Free fatty acids are released by lipoprotein lipase (LPL)
from chylomicron- or VLDL-TAG and then transported into the cardiomyocytes by
diffusion or via protein-mediated uptake. The proteins which mediate free fatty acids
uptake involve the cluster of differentiation 36 (CD36), fatty acid transport protein (FATP)
and plasma membrane fatty acid binding protein (FABPpm). In the process of proteinmediated fatty acid uptake, the fatty acids are initially bound to FABPpm, and then
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transported via FAT/ CD36 or FATP1/6. After transporting into the cytosol, the fatty acids
are used for ATP production by mitochondrial β-oxidation, participate in anabolic
metabolism into the endogenous TAG pool, or contribute to membrane synthesis through
the production of phospholipid (6).
The healthy heart is very flexible in its regulation of overall energy metabolism. However,
the balance between energy demand and supply is disturbed under pathological conditions.
For example, the increase of fatty acid supply and the subsequent increase of fatty acid
uptake induce the lipid accumulation in the heart (7). It is also postulated that mitochondrial
dysfunction results in lipid accumulation in the heart by impairing fatty acid β-oxidation
(8-10). Excessive lipid accumulation in the heart induces cardiac lipotoxicity which is
associated with insulin resistance, cardiomyocyte apoptosis and subsequent cardiac
dysfunction (4, 11). As described above, excessive fatty acids accumulated in the
cardiomyocytes have several fates. The excessive fatty acids may undergo β-oxidation in
the mitochondria for energy metabolism or be stored as TAG (4, 7). However, when the
capacity for mitochondrial β-oxidation of fatty acids cannot keep up with the excessive
uptake of fatty acids, lipid intermediates will accumulate, including TAG, diacylglycerols
(DAGs), ceramides, long-chain acyl CoAs, and acylcarnitines (4, 12, 13). The
accumulation of these toxic lipid intermediates may result in mitochondrial dysfunction
(14, 15), insulin resistance (16-19), cellular apoptosis (20, 21) and ventricular dysfunction
(22-24).
Palmitate (PA) is the most common saturated fatty acid found in western diets (25).
According to the World Health Organization, consumption of palmitate increases the risk
of developing cardiovascular diseases (26). Palmitate, a saturated fatty acid, has been
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widely used in the study of cardiac lipotoxicity. Palmitate-treated neonatal rat
cardiomyocytes have elevated reactive oxygen species (ROS) and changes in
mitochondrial morphology which are accompanied by the loss of mitochondrial reticulum,
suggesting increased mitochondrial fission (27). The level of mitochondrial ROS correlates
with mitochondrial dysfunction and apoptosis in cardiomyocytes induced by palmitate (27,
28). Palmitate treatment can also result in down-regulation of peroxisome proliferatoractivated receptors (PPARs), which in turn, impair the expression of important proteins
involved in mitochondrial β-oxidation (29). Nevertheless, the molecular mechanisms by
which palmitate induces mitochondrial dysfunction and cell death have not been fully
addressed.

1.2

Junctophilin-2

Junctophilin-2 (JPH2) is encoded by the JPH2 gene which was discovered about 2 decades
ago (30). There are 4 members in the junctophilin protein family (JPH1-4). They bridge
the physical gap between the plasma membrane and the sarcoplasmic/endoplasmic
reticulum (SR/ER) in excitable cells (31). JPH2 is the main junctophilin isoform in the
heart, although JPH1 is also expressed to a lesser extent (30). JPH1 is the major isoform in
skeletal muscle and JPH3 and JPH4 are neuronal isoforms found in brain (32).
Junctophilins are highly conserved molecules. There are 4 different components of JPH2
(33) (Figure 1). The 8 ‘membrane occupation and recognition nexus’ (MORN) motifs
(~330 amino acids) in the N-terminal region are thought to mediate attachment to the
plasma membrane. The MORN motif region is followed by a well-conserved α-helical
domain (~100 amino acids) which serves as the structural basis for the maintenance of a
uniform distance between the plasma membrane and the SR/ER. There is also a putative
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divergent region which exhibits a high degree of conservation (83%−91%) across species,
but shows poor conservation across the 4 JPH isoforms (15%−17%). The function of this
domain is not clear presently, but it may be associated with isoform-specific JPH functions.
Finally, JPH2 binds to the ER/SR membrane by a C-terminal, 22-amino acid
transmembrane anchor (30).
JPH2 is a membrane-binding protein that maintains a fixed distance between the plasma
membrane and the SR/ER, which plays an important role for proper Ca2+-induced Ca2+
release during the excitation-contraction process (31). Also, JPH2 is essential for the
development of postnatal T-tubules in mammals (34, 35). It can also maintain the
architecture of the junctional membrane complexes (JMCs) and stabilize local ion channels
in mature cardiomyocytes (36). A recent study also shows that JPH2 can stabilize the
activity of ryanodine receptor 2 (RyR2) in cardiomyocytes (36). Interestingly, it is recently
found that JPH2 can be cleaved by the Ca2+ dependent protease, calpain under stress and
the liberated N-terminal fragment of JPH2 (JP2NT) can serve as a transcription regulator,
inducing cardioprotective transcriptional reprogramming (37). All of these prior findings
underscore an important role of JPH2 in cardiac pathophysiology. In line with this, JPH2
dysfunction of mutations or down-regulation has been associated with hypertrophic
cardiomyopathy, arrhythmias, and heart failure (35).
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Figure 1: JPH2 structure and Ca2+ cycling in cardiomyocytes.
JPH2 is composed of the N-terminal MORN motifs, alpha helix region, divergent region
and transmembrane domain. In cardiomyocytes, the entry of a small amount of Ca2+ via
VGCC triggers the opening of RyR2 and the release of a large amount of Ca2+ from the SR,
a process described as Ca2+-induced Ca2+ release or Ca2+ coupling. The ensuing increase of
cytoplasmic Ca2+ enables contraction. Finally, Ca2+ is removed from the cytoplasm back
into the SR by SERCA pump and out of the cell by NCX. JPH2: junctophilin-2; VGCC:
voltage-gated Ca2+ channel; RyR2: ryanodine receptor-2; SERCA: sarco/endoplasmic
reticulum Ca2+ ATPase pump; NCX: Na+/Ca2+ exchanger; PM: plasma membrane; SR:
sarcoplasmic reticulum; MORN: membrane occupation and recognition nexus; TMD:
transmembrane domain.

1.2.1

JPH2 in T-tubule maturation

Knockdown of JPH2 by cardiac-specific short hairpin RNA (shRNA) in mice destroys the
formation of mature T-tubules within the first few weeks of life (35). Conversely, the
maturation of T-tubules occurs earlier in mice over-expressing JPH2 (35). This study
suggests that JPH2 is highly involved in the development of T-tubules to induce membrane
invagination. T-tubule architecture has been reported to be pathologically remodeled in
both patients and animal models with failing hearts (38). A high rate of mortality with rapid
development of systolic heart failure is found in mice with acute conditional cardiac
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shRNA-mediated knockdown of JPH2 (39). Similarly, JPH2 expression is decreased in the
myocardial ischemia model with loss of colocalization of JPH2 and RyR2 (40). While the
loss of JPH2 has yet to be studied in patients with more diverse cardiac disease etiologies,
the disruption of T-tubule architecture which occurs in ischemic heart disease, idiopathic
dilated cardiomyopathy, and hypertrophic cardiomyopathy (HCM) is likely a very early
event in failing hearts (34, 41, 42).

1.2.2 JPH2 in the postnatal development of junctional membrane complexes
(JMCs)
JPH2 can anchor T-tubules and SR. JPH2 null mice are embryonically lethal by Day E10.5
when the heart normally initiates contractile function, demonstrating the important
function of JPH2 (30). There is an extensive loss of JMCs in the JPH2 null mice in
association with spontaneous SR Ca2+ release and irregular Ca2+ transients, indicating that
JPH2 is very important in the postnatal development of JMCs (36). Cardiacspecific JPH2 knockdown reduces the number of JMCs, increases the variability of the
distance between the plasma membrane and the SR/ER and results in impaired cardiac
contractility, leading to heart failure and increased mortality (39). JPH2 deficiency affects
T-tubule elements preferentially, suggesting that longitudinal tubule elements may be
JPH2 independent, which is correlated with changes in T-tubule structure and JPH2 downregulation in heart failure (43).

1.2.3 JPH2-mediated regulation of RyR2
While the importance of JPH2 for T-tubule function has received significant attention, Ttubule independent functions of JPH2 in cardiomyocytes have just been recognized.
Decreased or dysfunctional JPH2 results in RyR2 dysfunction in cardiomyocytes,
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indicating a novel role of JPH2 in maintaining RyR2 stability, which is independent of the
T-tubule system (35). Studies using mice with a JPH2 missense mutation (JPH2-E169K)
reveal that dysfunctional JPH2 disrupts the interaction between RyR2 and JPH2 and thus
leads to Ca2+ leak from RyR2 (37, 44). This results in an increase in diastolic Ca2+ and
promotes the activation of sarcolemmal Na+-Ca2+ exchanger (NCX), thereby creating a net
depolarizing current, leading to delayed afterdepolarizations (DADs), an important
mechanism contributing to atrial arrhythmias (45-47). Therefore, arrhythmogenic SR
Ca2+ leak may be initiated by the loss of the stabilizing interaction between JPH2 and RyR2.
However, the molecular mechanisms by which JPH2 stabilizes RyR2 remain unknown.
Given the importance of Ca2+ cycling in cardiac bio-pathology, this novel function of JPH2
may be important in maintaining cardiac normality, suggesting that a reduction and/or
dysfunction of JPH2 may play a role in cardiac injury under stress.

1.2.4 Regulation of JPH2 in cardiomyocytes
JPH2 down-regulation has been involved in various cardiac diseases and some mechanisms
have been suggested to explain the loss of JPH2 (Figure 2). It is shown that JPH2 is the
target of microRNA 24 (miR-24), which may be responsible for decreased JPH2 in cardiac
hypertrophy (48). In failing hearts, miR-24 is up-regulated (48, 49), and is associated with
the down-regulation of JPH2 (48, 50). Silencing miR-24 prevents the development of heart
failure which is said to be due to maintaining the expression of JPH2 and T-tubule integrity
(51), confirming the relationship between miR-24 and JPH2. Another study finds that JPH2
is the target of miR-34a. Initial cardiac defects diminish RBFox2 (RNA binding protein)
expression, which induces the expression of miR-34a, and elevated miR-34a targets JPH2
to down-regulate JPH2 expression, which further results in heart dysfunction, leading to
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progressive heart failure. The administration of a miR-34a mimic is sufficient to induce
cardiac defects. However, antagonism of miR-34a alleviates RBFox2 depletion-induced
heart dysfunction (52).
JPH2 down-regulation has also been attributed to cleavage by calpain in failing hearts (53).
Calpain is a protease that is activated by elevated intracellular Ca2+ (54, 55). Activation of
the heterotrimeric G protein Gαq can activate calpain. Loss of T-tubule integrity, together
with a pronounced decrease in full-length JPH2 are found in a transgenic mouse with
inducible activation of the heterotrimeric G protein Gαq. Calpain inhibitors prevent Gαqmediated JPH2 down-regulation, suggesting calpain is responsible for generation of the
JPH2 cleavage fragments (53). Furthermore, decreased full-length JPH2 level is found in
ischemia-reperfusion injury, though no cleavage fragment is detected (56).
A most recent study shows that JPH2 is also a target of matrix metalloproteinase-2 (MMP2)
in myocardial ischemia-reperfusion (IR) injury (57). MMP2 is a Zn2+ and Ca2+-dependent
protease that is activated by oxidative stress in myocardial IR injury which cleaves both
intracellular and extracellular substrates. IR injury increases the degradation of JPH2 and
impairs the recovery of cardiac contractile function. ARP 100, a MMP inhibitor, attenuates
JPH2 proteolysis and improves the recovery of cardiac contractile function in IR hearts. In
addition, MMP2 is co-localized with JPH2 in IR hearts. It is confirmed that JPH2 is
susceptible to proteolysis by MMP2 and multiple cleavage sites have been predicted (57).
In addition to its down-regulation, loss of normal subcellular localization of JPH2 due to
microtubule polymerization also contributes to JPH2 dysregulation (58). Microtubule
densification, defined as the increase in microtubule density due to enhanced microtubule
polymerization, is commonly found in human failing hearts and mouse models of heart
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failure (56, 59). Zhang et al. observed that the subcellular distribution of JPH2 is linked to
microtubule dynamics (58). Under cardiac stress, redistribution of JPH2, resulting from the
densification of the microtubule network, induces T-tubule remodeling and excitationcontraction coupling dysfunction, contributing to the development of heart failure (58).

Figure 2: Mechanisms of JPH2 dysregulation in heart diseases.
Depicted are miRNA-mediated gene silencing by miR-24 and miR-34, calpain-mediated
proteolysis, MMP2-mediated proteolysis, and redistribution to the cell periphery in
response to microtubule polymerization. JPH2: junctophilin-2; VGCC: voltage-gated Ca2+
channel; RyR2: ryanodine receptor-2; miR: micro RNA; MMP2: matrix metalloproteinase2; PM: plasma membrane; SR: sarcoplasmic reticulum.

1.2.5 JPH2 encodes transcription regulator under stress
JPH2 is required for normal E-C coupling. After cardiac stress, Ca2+ overload induces
protease calpain activation. JPH2 is cleaved by calpain and liberates the N-terminal
fragment (JP2NT), disrupting the ultrastructure of the E-C coupling machinery. JP2NT
translocates to the nucleus via a conserved nuclear localization signal, binds to the TATA
box of genomic DNA via the alanine-rich region and associates with a MEF2 response
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element to repress the transcription of genes that control deleterious cardiac remodeling
(37). Transgenic over-expression of JP2NT in mice results in attenuated pathological
remodeling in response to cardiac stress. Conversely, loss of nuclear JP2NT function
accelerates stress-induced development of hypertrophy and heart failure in mutant mice
(37). This finding reveals that cardiomyocytes possess a self-protective mechanism in
failing cardiomyocytes that transduces mechanical information (E-C uncoupling) into
transcriptional reprogramming in the stressed heart (37).

1.3

Endoplasmic reticulum stress

The endoplasmic reticulum (ER) is a multifunctional intracellular organelle supporting
many processes required by almost every mammalian cell, including cardiomyocytes. It
performs diverse functions, including protein synthesis, translocation across the membrane,
integration into the membrane, folding and posttranslational modification (60). Also, the
ER participates in the synthesis of phospholipids and steroids on the cytoplasmic side of
the ER membrane (61). It is also the major intracellular Ca2+ reservoir in the cell and plays
an important role in the regulation of Ca2+ homeostasis in cardiomyocytes (62, 63).
ER stress is a condition that is accelerated by the accumulation of unfolded/misfolded
proteins after the disturbance in ER quality control in a variety of physiological and
pathological conditions (64). Upon ER stress, cells activate a series of complementary
adaptive mechanisms to cope with protein-folding alterations, which together are known
as the unfolded protein response (UPR) (63). The UPR transduces information about the
protein-folding status in the ER lumen to the nucleus and cytosol to buffer fluctuations in
unfolded/misfolded protein load (65, 66). When cells undergo irreversible ER stress, this
pathway eliminates damaged cells by apoptosis (67). ER stress is found to be involved in
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many cardiovascular diseases, such as ischemic heart disease, atherosclerosis, cardiac
hypertrophy, cardiac lipotoxicity, heart failure etc. (68).

1.3.1 Unfolded protein response (UPR)
UPR is a defense mechanism which removes the unfolded/misfolded proteins and prevents
their accumulation. The UPR is activated by 3 main transmembrane stress sensors,
including inositol-requiring protein 1 α (IRE1α), protein kinase RNA-like ER kinase
(PERK) and activating transcription factor 6 (ATF6) and results in a lot of cellular
responses (63, 68).
In the IRE1α pathway, IRE1α dimerization triggers the activation of its RNase, which
promotes the mRNA encoding unspliced X box-binding protein 1 (XBP1) and produces a
transcription factor, spliced XBP1 (XBP1s). XBP1s regulates the transcription of genes
which encode proteins involved in protein folding, protein quality control, phospholipid
synthesis and ER-associated degradation (ERAD). IRE1α can degrade some mRNAs
through regulated IRE1-dependent decay (RIDD). IRE1α can also trigger ‘alarm stress
pathways’, including those driven by nuclear factor-κ B (NF-κ B) and JUN N-terminal
kinase (JNK) (63, 69).
In the PERK pathway, PERK activation can phosphorylate the initiation factor eukaryotic
translation initiator factor 2α (eIF2α) to prevent the synthesis of general protein. PERK
activation can also phosphorylate the nuclear factor erythroid 2-related factor 2 (NRF2)
which is a transcription factor controlling redox metabolism. eIF2α phosphorylation allows
the translation of the transcription factor ATF4, which regulates the transcription of genes
participating in apoptosis, autophagy, antioxidant responses and amino acid metabolism.
(63, 70).
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In the ATF6 pathway, there is a basic Leu zipper (bZIP) transcription factor in the cytosolic
domain of ATF6 and it is localized to the ER. When cells undergo ER stress, ATF6 can
be transported to the Golgi apparatus by interacting with the coat protein II (COPII)
complex. Then, ATF6 is processed by site 1 protease (S1P) and S2P and its cytosolic
domain fragment (ATF6f) is released. ATF6f regulates the up-regulation of genes encoding
XBP1 and ERAD components (63, 71).
These 3 branches of ER transmembrane sensors can trigger adaptive responses through the
splicing of XBP1, the phosphorylation of eIF2α and the translation of transcription factor
ATF4. Finally, the unfolded protein response related genes are induced, including
CCAAT-enhancer-binding protein (C/EBP) homologous protein (CHOP), chaperones
glucose-regulated protein-78 (GRP78), GRP94 etc (2).

1.3.2 Calcium homeostasis and ER stress
As described above, ER stress is induced by the accumulation of unfolded/misfolded
proteins. It is shown that oxidative stress, ischemia, disturbance of Ca2+ homeostasis and
high-fat diet are related to the induction of ER stress (2, 72-74).
In cardiomyocytes, sarcoplasmic/endoplasmic reticulum (SR/ER) is the major intracellular
Ca2+ reservoir. The entry of a small amount of Ca2+ through L-type Ca2+ channels on
plasma membrane during an action potential triggers the synchronized opening of RyR2
on the SR which allows a rapid and transient release of Ca2+ from the SR. This process is
described as Ca2+-induced Ca2+ release (CICR) or Ca2+ coupling. The subsequent elevation
of intracellular Ca2+ promotes the contraction of cardiomyocytes. Finally, Ca2+ is removed
from the cytoplasm back into the SR by sarcoplasmic/endoplasmic reticulum ATPase
(SERCA2a) pump and out of the cell by Na+-Ca2+ exchanger (NCX) (Figure 1) (75).
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Ca2+ homeostasis refers to the regulation of Ca2+ concentration in the body. This
concentration is tightly controlled by a stabilizing system consisting of Ca2+ channels and
Ca2+ buffering proteins (76). Ca2+ homeostasis is crucial for cell survival. The disruption
of Ca2+ homeostasis induces ER stress and leads to the apoptotic cell death (76).
Reticulocalbin 1 (RCN1), a target of NF-κB, suppresses ER Ca2+ release by binding to
inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) and decreases the UPR, thereby
inhibiting ER stress-induced apoptosis (77). The Ca2+ channel RyRs are involved in ER
stress and β-cell death (78). In this study, ER stress following SERCA inhibition is
attenuated by blocking RyRs. Conversely, stimulation of RyRs accelerates thapsigargininduced ER depletion and apoptosis (78).

1.3.3 ER stress and apoptosis
If ER stress is prolonged or overwhelming, it can induce apoptotic cell death through
CHOP and/or other pathways (79).
CHOP, also known as growth arrest- and DNA damage-inducible gene 153 (GADD153),
is a 29 kDa protein with 169 (human) or 168 (rodents) amino-acid residues. It is composed
of 2 known functional domains, an N-terminal transcriptional activation domain and a Cterminal basic-leucine zipper (bZIP) domain (80). CHOP is ubiquitously expressed at very
low levels and is present in the cytosol under nonstressed conditions. However, ER stress
can induce the expression of CHOP and lead to its accumulation in the nucleus (81). CHOP
works as a transcription factor that regulates genes involved in apoptotic cell death (82,
83).
CHOP is the main up-regulated pro-apoptotic player during excessive ER stress (84). The
transcriptional induction of CHOP is controlled by the PERK–ATF4 axis in a positive
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manner (79) and this up-regulation switches the consequences of the UPR from
proadaptive to proapoptotic signaling. In addition to the inhibition of Bcl-2, overexpression of CHOP promotes several mechanisms of apoptosis including the stimulation
of caspase activity (85) and Bax translocation from cytosol to mitochondria (86).
Knockdown of CHOP reduces ER stress-mediated apoptosis (82) and over-expression of
CHOP triggers apoptosis after treatment with ER stress inducers (85).

1.3.4 ER stress in cardiovascular diseases
Recent animal and human studies have demonstrated that ER stress is implicated in the
pathophysiology of various cardiovascular diseases (83, 87). In ischemic heart disease, cell
death is reduced in cardiomyocytes after the inhibition of ER stress and silencing of the
IRE1 gene (88). In addition, the ER may induce apoptotic signaling by increasing the
expression of CHOP involved in the transition from cardiac hypertrophy to heart failure
(83). In atherosclerosis, the intensity of ER stress increases and the PERK pathway induces
cell death by activating IRE1α and inducing apoptosis signaling pathways (87).
Notably, ER stress is induced and has been implicated in cardiac lipotoxicity. Our previous
work found that in high fat diet fed mouse hearts, ER stress was induced and apoptosis was
increased. In addition, palmitate also induced ER stress and apoptotic cell death compared
to oleate in cultured cardiomyocytes (2). These results mean that ER stress is induced and
detrimental under cardiac lipotoxicity condition. However, sequestration of fatty acids in
triglycerides can prevent ER stress in an in vitro model of cardiomyocyte lipotoxicity (89).
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1.4

Apoptosis in cardiomyocytes

1.4.1 Apoptosis: programmed cell death
Apoptosis is widely known as programmed cell death which may occur in multicellular
organisms. Apoptosis can result in characteristic cell changes and death. There are 3 classic
signaling pathways of apoptosis, including the intrinsic (mitochondrial) pathway, the
extrinsic (death receptor) pathway, and the ER stress pathway.

1.4.1.1 The morphological change of apoptosis
Apoptosis is an organized self-killing process (90). The cells begin to shrink after the
activation of apoptotic pathways. Morphological changes include smaller cellular size,
denser cytosol, chromatin condensation and more tightly packed organelles. Subsequently,
apoptotic bodies are formed, where the plasma membrane encloses the tightly packed
organelles with or without a nuclear fragment. At the same time, nuclear proteins and
cytoskeletal proteins are cleaved and degraded by caspases in the execution phase of
apoptosis (91). Finally, macrophages will phagocytose the apoptotic bodies through
binding to the externalized phosphatidylserine, which is located on the outer leaflet of the
bilayer (92).
Many cellular killing and engulfment proteins are involved in the apoptotic process, among
which caspases play very important roles. Once the apoptotic pathways are initiated, the
activated caspases will activate other procaspases, promoting the protease cascade and then
amplifying the apoptotic signal irreversibly (93). Recently, more than 10 caspases have
been found and recognized during the apoptotic process, including the initiators (caspase2,-8,-9,-10), the executioners (caspase-3,-6,-7) and other regulators (caspase-11,-12,-13,14) (91, 94).
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1.4.1.2 The extrinsic pathway
The extrinsic pathway is triggered by transmembrane death receptors which belong to
tumor necrosis factor (TNF) receptor family and contain a death domain. Several classical
ligands and their corresponding death receptors are apoptosis-stimulating fragment ligand
(FasL)/FasR, and TNF-α/TNFR1. TNF-related apoptosis-inducing ligand (TRAIL)/DR4
and TRAIL/DR5 will transmit the death signals from cell surface to intracellular pathways
through the death domain. For example, after the binding of FasL to FasR or TNF-α to
TNFR1, the fas-associated death domain (FADD) will be recruited and bound to the ligandreceptor complex (95). Subsequently, FADD will activate procaspase-8 and form a deathinducing signaling complex (DISC) (96). Finally, caspase-8 activated by DISC will trigger
the activation of caspase-3 and caspase-7 and then induce the apoptotic cascade, leading to
the execution phase of apoptosis (97).

1.4.1.3 The intrinsic pathway
The intrinsic pathway is mitochondrial-triggered. This pathway is usually activated by
stimuli including hypoxia, hyperthermia and the absence of growth factors. These stimuli
promote the opening of mitochondrial permeability transition pore (MPTP) and then
accelerate the release of some pro-apoptotic proteins including cytochrome c (Cyt c) and
apoptosis-inducing factor (AIF) from the mitochondrial intermembrane space into the
cytosol (98). Cyt c will bind and activate apoptotic protease activating factor 1(Apaf-1) as
well as procaspase-9 and then result in the activation of caspase-9, which in turn activates
caspase-3 and caspase-7 (99, 100). However, AIF will translocate to the nucleus and induce
chromatin condensation and DNA fragmentation in a caspase-independent way in the late
phase of apoptosis (101).
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Notably, intrinsic pathway-induced apoptosis is regulated by B-cell lymphoma 2 (Bcl-2)
family proteins (102) which are in the outer membrane of mitochondria. Bcl-2 family
proteins can control the permeability of mitochondrial membrane and participate in the
regulation of the release of Cyt c. Bcl-2 family proteins can be classified into pro-apoptotic
and anti-apoptotic proteins. The pro-apoptotic proteins include Bax, Bad, Bak, Bim, Bid,
Puma and BNIP3 (103); while the anti-apoptotic proteins contain Bcl-2, Bcl-XL, Bcl-x,
and BAG (104). Bax can be up-regulated by the tumor suppressor protein p53 in the
nucleus or mitochondria (np53 or mp53) (100, 105). However, Bcl-2 or Bcl-xL may block
np53 or mp53-induced apoptosis (104-106). When p53 is down-regulated, Bax and
caspase-3 are also down-regulated in the heart (107). Interestingly, there is interaction
between the extrinsic and intrinsic pathways. It is found that Fas-mediated apoptosis can
also induce mitochondrial damage through the caspase-8-mediated cleavage of Bid (108).

1.4.1.4 The ER stress pathway
The ER stress pathway is a relatively newly described pathway contributing to the
regulation of apoptosis. It is commonly induced under some physiological or pathological
conditions including protein folding, disruption of intracellular Ca2+ homeostasis, hypoxia,
oxidative stress, ischemia and lipid metabolic disorders (65, 109). Although ER stress is
important for cell survival (65), it can also result in apoptosis under prolonged or chronic
stimulation (110). As described before, ER stress is sensed by UPR which is activated by
3 main stress sensors including IRE1α, PERK and ATF6 (62).
In the IRE1α pathway, IRE1α interacts with TRAF2 (tumor necrosis factor receptor
(TNFR)-associated factor-2) and initiates JNK expression which is demonstrated to be
involved in cell death (111, 112). Therefore, it is assumed that JNK is associated with IRE1-
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mediated apoptosis. Notably, IRE1α can be activated through binding to Bak and Bax (113).
Procaspase-12 is activated through interacting with IRE1α-TRAF2 complex (114). In
addition, IRE1α may promote apoptosis by activating the RIDD pathway (79, 115);
however, the specific mechanism is unclear. Interestingly, IRE1α can also splice and
activate XBP1 mRNA (116) which participates in cell survival. As a result, IRE1α is a
crucial protein and plays an important role in the regulation of apoptosis and survival under
ER stress.
In the PERK pathway, PERK promotes the phosphorylation of eIF2α and induces the
translation of ATF4, which participates in proapoptotic process. ATF4 induces the
expression of CHOP. CHOP can suppress the expression of Bcl-2 (85) and increase the
expression of Bim, Puma and Bax (117-120). Also, CHOP can activate ER oxidase 1α
(ERO1α) (121) and induce Ca2+-dependent apoptosis through the CHOP-ERO1α-IP3R1Ca2+-CaMKII pathway (122). Caspase-12 and Bid are also reported to be involved in
CHOP-ERO1α-IP3R- Ca2+-calpain pathway during ER stress (123, 124). Notably, CHOPand IRE1α-induced apoptosis can be repressed by a phenomenon called pre-conditioning,
where low-level ER stress can partially prevent UPR before a robust UPR activation (125).
In the ATF6 pathway, ATF6 can activate XBP1 and exert a prosurvival effect (116).
Conversely, inhibition of ATF6 can promote apoptosis (126). However, the detailed
mechanism of ATF6-involved apoptosis needs further investigation.

1.4.2 Apoptosis in cardiac lipotoxicity
1.4.2.1 Cardiac lipid overload induces apoptosis
Cardiac lipid overload is associated with, and thought to contribute to, the initiation of the
apoptotic cascade. Studies, primarily in isolated cardiomyocytes, have implicated saturated
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FAs as a primary cause of apoptosis (127). Treatment of isolated neonatal rat ventricular
myocytes with palmitic acid can generate cytoplasmic ceramide, which activates JNK1/2
that interacts with Bax in the mitochondrial membrane, leading to apoptosis associated
with cardiolipin loss, cytochrome c release, mitochondrial swelling, and DNA laddering
(127, 128).
Accumulation of FAs has been linked to the induction of ER stress. Specifically, palmitateinduced ER stress has been considered to be a secondary event that follows oxidative stress
and the generation of ROS, and results in an induction of eukaryotic elongation factor (eEF)
1A-1, which interferes with the integrity of the cytoskeleton and causes cell death (129). A
more direct mechanism of palmitate-induced ER stress has also been proposed in the same
study. This mechanism involves the incorporation of palmitate in phospholipid and TG
species in microsomal membranes so that ER membrane integrity is compromised and
protein-folding chaperones are redistributed to the cytosol (130). Another study has
reported that the esterification of palmitate can directly cause ER fission (131). Intensive
ER stress may result in apoptosis.

1.4.2.2 Apoptosis induces cardiomyocyte dysfunction and cardiac
remodeling
Cardiac lipid overload is associated with, and thought to contribute to, the initiation of the
apoptotic cascade. Cardiomyocyte loss via apoptosis together with pathological
cardiomyocyte hypertrophy may produce progressive myocardial dysfunction, leading to
heart failure (132). Cardiac hypertrophy occurs in response to long-term increases in
hemodynamic load related to various physiological and pathological conditions. The
hypertrophic process is characterized by structural changes at the cardiomyocyte level that
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are translated into alterations in chamber size and geometry, collectively called remodeling
(133, 134). Functional benefits of the hypertrophic response include an increase in the
number of contractile elements, a lowering of wall stress through increased wall thickness
in concentric hypertrophy, and an increase of stroke volume by increasing end-diastolic
volume in eccentric hypertrophy (134). By contrast, pathological forms of cardiac
hypertrophy develop in response to persistent increases in hemodynamic load.
Epidemiological studies have demonstrated that pathological cardiac hypertrophy is a risk
factor for future cardiac events (135, 136). Indeed, pathological cardiac hypertrophy often
enters a phase of pathological remodeling that leads to contractile dysfunction, heart failure
and sudden death (137).
Cardiomyocyte loss via apoptosis also participates in cardiac fibrosis (138). Fibrosis is the
excessive deposition of extracellular matrix (ECM), such as collagens and fibronectin,
resulting in the excessive accumulation of fibrous connective tissue (139, 140). Fibrosis is
an essential process in the repair of damaged tissues and wounds, but its accumulation in
organs and tissues can lead to scarring, organ dysfunction and, ultimately, failure (138).
Paracrine signaling from fibroblasts induces cardiomyocyte hypertrophy. Fibroblasts can
produce a number of cytokines and growth factors, including TGF-β, interleukin-33 (IL33), fibroblast growth factor 2 (FGF2), tumor necrosis factor alpha (TNF-α), insulin growth
factor (IGF1) and endothelin-1 (ET-1), which directly affect cardiomyocyte function in
vitro and/or in vivo (141-148). Myofibroblasts express a large number of structural ECM
proteins and matrix remodeling proteins and together determine the functionality of the
ECM. Thus, besides the amount of ECM, the level of collagen cross-linking also strongly
determines the development of diastolic and systolic dysfunction (137, 149-154). Fibrosis
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also disturbs cardiac electrophysiology and induces rhythm disturbances. In mice, TGF-β
over-expression results in atrial fibrosis, without ventricular involvement, and these mice
develop inducible atrial fibrillation (AF) (155, 156). Finally, fibrosis limits nutrient supply
to the myocardium by limiting cardiac function and myocardial blood flow (149).
Perivascular fibrosis in coronary arteries reduces oxygen delivery toward myocardial tissue,
reduces coronary reserves and promotes myocardial ischemia (137, 154). Thus, fibrosis
impairs cardiac function by at least 3 mechanisms, including induction of myocardial
stiffness, induction of atrial fibrillation and limiting oxygen and nutrient supply to the
stressed myocardium. These will promote cardiomyocyte hypertrophy and heart failure.

1.5

Rationale

Cardiac lipotoxicity is a critical mechanism underlying cardiac complications in patients
with obesity and/or diabetes. Cardiac lipotoxicity results from the accumulation of lipid
intermediates in non-adipose tissue, leading to cellular dysfunction and death. However, it
needs to be further elucidated how the accumulation of lipids causes cellular dysfunction
and death in the heart.
In our lab, we previously reported that palmitate treatment activated calpain and induced
ER stress and subsequent cell injury when compared to oleate in cardiomyocytes (2). We
further found that the protein levels of JPH2 were reduced in high fat diet-fed mouse hearts,
which correlated with myocardial injury and dysfunction (2). These previous findings raise
an important possibility that decreased JPH2 may play a role in mediating ER stress and
apoptosis in cardiomyocytes during lipotoxicity and thus, up-regulation of JPH2 may
protect cardiomyocytes against lipotoxicity.
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Understanding the role of JPH2 in cardiac lipotoxicity is clinically relevant because the
protein levels of JPH2 are reduced in various human diseased hearts. This study determines
whether and how JPH2 provides a cardiac protective role in lipotoxicity.

1.6

Hypothesis

JPH2 will protect cardiomyocytes against palmitate-induced injury by inhibiting
endoplasmic reticulum (ER) stress.

1.7

Specific aims

1.7.1 To confirm that palmitate induces cell injury in cardiomyocytes.
1.7.2 To determine if JPH2 knockdown enhances whereas JPH2 overexpression attenuates palmitate-induced cell injury in cardiomyocytes.
1.7.3 To determine the mechanism by which JPH2 protects cardiomyocytes
against palmitate-induced injury by modulating calcium release from RyR2
and inhibiting ER stress.
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Chapter 2

2

Materials and Methods

2.1

Animals

This investigation conforms to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011). All
experimental procedures were approved by the Animal Use Subcommittee at the
University of Western, Ontario, Canada. Breeding pairs of C57BL/6 mice and C57BL/6
background CHOP-/- mice were purchased from the Jackson Laboratory (Bar Harbor,
Maine). Mice used in this study, including controls, were littermates.
For genotyping of CHOP-/- mice, 1-2 mm of the tip of the tail was cut from CHOP-/- mice
and put into a microtube (1.5mL). The DNA from CHOP-/- mice was extracted. Briefly, the
tail was lysed in solution A (Table 1) and incubated in a metal bath at 100 °C for 45 min.
Then, the microtube containing solution A was cooled to room temperature. The
stabilization buffer solution B (Table 2) was added to the microtube and mixed completely.
After that, the DNA lysate was centrifuged at 10,000g for 5 min and the supernatant was
ready for PCR (FroggaBio). The PCR system (Table 3) and protocol (Table 4) for the gene
amplifying of CHOP are listed below. It was confirmed that there was no CHOP gene
expression in CHOP-/- mice.
Table 1: Components of Solution A (100mL)
NaOH
EDTA
H2 O

100 mg
7.4 mg
100 mL
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Table 2: Components of Solution B (100mL)
Tris-HCl (40mM, pH=5.0)
H2 O

0.48 g
100 mL

Table 3: Components of PCR System (25µL)
10X Buffer
2.5 mM dNTP
Taq DNA polymerase (5U/µL)
25uM Primer
H2 O
Template DNA

2.5 µL
2 µL
0.25 µL
0.4 µL
17.85 µL
2 µL

Table 4: Protocol of PCR for CHOP-/- Mouse

2.2

Step

Temperature (ºC)

Time

1
2
3
4
5
6
7
8
9
10
11

94
94

2 min
20 sec
15 sec
10 sec

65（- 0.5 ºC per cycle decrease）
68
Repeat step 2-4 for 10 cycles
94
60
72
Repeat step 6-8 for 30 cycles
72
10

15 sec
15 sec
10 sec
2 min
∞

Isolation and culture of neonatal mouse cardiomyocytes

Primary cardiomyocytes were isolated from neonatal mice born within 24 hours. Briefly,
after sterilizing with 75% alcohol, the neonatal mice were killed by decapitation. The chest
was opened through a sternal approach and the hearts were harvested and placed into DHank's solution (50 mL tube, Table 5). The hearts were washed in D-Hank's solution 2
times to remove the blood. Then, each heart was cut into 5–6 pieces by a surgical blade
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and washed in D-Hank's solution for the third time. The heart pieces were then subjected
to the following 3 steps of digestion. (1) Heart tissues were incubated with Liberase
Blendzyme (2.5 mg/mL, Roche Applied Science) which was dissolved in sterile water in a
water bath at 37°C for 10 min. The supernatant was discarded. (2) The tissues were
incubated with fresh Liberase Blendzyme solution at 37°C for 15 min. During the
incubation, the heart pieces were gently shaken every 5 min. After 15 min, the heart pieces
were triturated to isolate the cardiomyocytes completely. The supernatant containing
isolated cardiomyocytes was collected and the culture medium DMEM containing 10%
NBCS (new-born calf serum) (Wisent Inc) was added to stop the digestion. (3) Step 2
described above was repeated. The supernatants from steps 2 and 3 were pooled and
centrifuged at 200 g for 5 min. The pellets containing the isolated cardiomyocytes were resuspended in 10% NBCS DMEM. Next, the suspended cells were seeded in a culture dish
which was placed in a CO2 incubator at 37°C for 120 min. This step allowed the fibroblasts
to adhere to the culture plate. After fibroblast adherence, cardiomyocytes were collected
and the cell number was counted. The cardiomyocytes were then seeded into a culture plate
which had been already plated with 1% gelatin (Sigma) at 37°C for 120 min in an incubator.
Finally, the plate containing cardiomyocytes was placed in a CO2 incubator at 37°C. After
overnight incubation, the cardiomyocytes were ready for various experiments. The
neonatal cardiomyocytes were characterized by the staining of tropnin and the purity level
was more than 95%.
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Table 5: Components of D-Hanks (1L)
KCl
KH2PO4
NaCl
D-Glucose
Phenol red

2.3

0.4 g
0.06 g
8g
1g
0.012 g

Adenoviral infection

Primary neonatal mouse cardiomyocytes were infected with recombinant adenoviral
vectors expressing junctophilin-2 (Ad-JPH2), shRNA for junctophilin-2 (Ad-shJPH2),
green fluorescent protein (Ad-GFP) or human influenza hemagglutinin (aa98-106) peptide
tag (Ad-HA). The adenoviral vectors were purchased from Vector Biolabs or SignaGen
Laboratories. The shRNA sequence of junctophilin-2 (Ad-shJPH2, mouse) is
CCTACATGGGCGAGTGGAA-TTCAAGAGA-TTCCACTCGCCCATGTAGGTTTTTT and the Genbank RefSeq is NM_021566. The titer of the recombinant adenovirus
was calculated based on its cytopathic effect (CPE) and the neonatal cardiomyocytes were
infected at a multiplicity of infection (MOI) of 100 plaque forming units per cell (100
PFU/cell). The day before the infection, neonatal cardiomyocytes were seeded in a 24-well
plate. The adenoviruses were thawed on ice, prepared in 10% NBCS DMEM and added to
the cardiomyocytes. After incubation for 4 hours at standard cell culture condition, the
cardiomyocytes were supplied with fresh culture medium. Neonatal cardiomyocytes were
collected for the following experiments. All the experiments were completed within 72
hours after adenoviral infection.
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2.4

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blot analysis

Cardiomyocytes were lysed with a cell lysis buffer (Table 6) and collected in microtubes
(1.5 mL). The cell lysates were disrupted by ultrasonic processor for 3 seconds and
centrifuged at 10,000 g for 10 min. Then, the protein concentration was detected by the
Bradford assay (Bio-Rad). In brief, the standards or samples were added to a 96-well plate.
Then, reagent A and reagent S were added to the well. In this step, proteins and copper
reacted in an alkaline medium. After that, reagent B was added to the well. In this step,
Folin reagent was reduced by the copper-treated protein and produced a characteristic blue
color which was detected at 490 nm. The standard curve was made and the concentration
of the proteins was calculated according to the color change. After that, the supernatant of
cell lysates was transferred into a new tube and adjusted to the same concentration by the
lysis buffer. The 6 X loading buffer (Table 7) was diluted with the supernatant of cell
lysates and the protein supernatant was incubated in a metal bath at 100 °C for 5 min to
denature the proteins.
Table 6: Components of Lysis Buffer (100 mL)
Tris-HCl (1M, pH=7.5)
SDS
EDTA (0.5M)
H2 O

5 mL
0.5 g
200 µL
94.8 mL

Table 7: Components of 6X Loading Buffer (100 mL)
Tris-HCl (1M, pH=6.8)
SDS
Bromophenol blue
Glycerol

37.5 mL
6g
30 mg
48 mL
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β-Mercaptoethanol
H2 O

9 mL
5.5 mL

After preparation of protein samples, the proteins were separated by SDS-PAGE. The gel
casting apparatus (Bio-Rad) was assembled and tested for leaking before the SDS-PAGE.
A resolving gel (Table 8) was then prepared and the concentration of which was dependent
on the size of the target protein in the samples. The mixture was transferred to the gel
casting apparatus and a water overlay was filled on the top of the resolving gel to avoid the
air interference. When the resolving gel had solidified after 30 min, the stacking gel was
made (Table 9) and filled on the top of the resolving gel. A clean comb was inserted into
the stacking gel to make space for the protein samples. The gel assembly was taken out of
the casting and put into the gel tank. Running buffer (Table 10) was poured into the tank
until above the top of the gel. 30 µg protein sample was loaded in the stacking gel well.
Then, the electrophoresis assembly was connected to the power supply set at 80V for 30
min and 100V for about 90 min until the running front reached the end of the gel.
Table 8: Components of Resolving Gel (10mL)
Concentration
H2 O
30% Acrylamide
Tris (1.5M, pH=8.8)
10% SDS
10% Ammonium persulfate (APS)
TEMED

10%
2.7 mL
3.35 mL
3.75 mL
100 µL
100 µL
4 µL

12%
2.05 mL
4 mL
3.75 mL
100 µL
100 µL
4 µL

Table 9: Components of Stacking Gel (3mL)
H2 O
30% Acrylamide
Tris (1.5M, pH=8.8)
10% SDS

2.05 mL
0.5 mL
0.375 mL
30 µL
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10% Ammonium persulfate (APS)
TEMED

30 µL
3 µL

Table 10: Components of Running Buffer (1L)
Tris base
3.03 g
Glycine
14.41 g
SDS
1g
H2 O
1000 mL
pH
8.3
After electrophoresis, the separated proteins were transferred to a polyvinyl difluoride
(PVDF) membrane (Froggabio). First, the transfer cassette equipment was immersed in
transfer buffer (Table 11) and the PVDF membrane was immersed in methanol. Next, the
cassettes were assembled in a sandwich structure: a sponge, a layer of blotting paper, a
PVDF membrane, electrophoresed gel, a layer of blotting paper and a sponge. Then, the
cassette was placed in the tank filled with transfer buffer and connected to the power supply
set at 350 mA for 90 min at 4°C.
Table 11: Components of Transfer Buffer (1L)
Tris base
Glycine
Methanol
H2 O

3.03 g
14.41 g
200 mL
800 mL

Upon completion of the run, the PVDF membrane was removed and placed in a blocking
buffer containing 5% non-fat milk at room temperature for 1 hour. The blocking buffer was
made by dissolving non-fat milk (Bio Basic) in tris-buffered saline containing Tween 20
(TBST, Table 12). This step was to block the non-specific binding sites. After that, the
primary antibodies were diluted with 5% bovine serum albumin (BSA, Sigma) in TBST
and the PVDF membranes were incubated with the primary antibodies in a tube which was
set on a rocking table at 4 °C, overnight. After incubation with the primary antibodies, the
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PVDF membranes were washed 3 times with TBST for 10 min each. The membranes were
then incubated with the secondary antibodies in a solution containing 5% non-fat milk in
TBST at room temperature for 1 hour. After incubation with the secondary antibodies, the
PVDF membranes were washed 3 times with TBST for 10 min each. Finally, the
membranes were immersed in enhanced chemiluminescence (ECL) reagent (Table 13) for
signal detection. The signal was visualized by an enhanced chemiluminescence-detection
system.
Table 12: Components of TBST (1L)
Tris base
NaCl
H2 O
pH

2.42 g
8g
1000 mL
7.6

Table 13: Components of Enhanced Chemiluminescence (ECL) Reagent (100mL)
Tris-HCl (1M, PH=8.5)
Cumaric acid (90mM)
Luminol (250mM)
H2 O2

Reagent A
100 mL
440 µL
1 mL
-

Reagent B
100 mL
60 µL

Table 14: Antibody Information for Western Blot
Antibody (Polyclonal)
JPH2 (Mouse)
CHOP (Rabbit)
GAPDH (Mouse)
Actin (Rabbit)

2.5

Company
Abcam
Cell Signaling
Santa Cruz
Cell Signaling

Molecular weight (kDa)
97
27
37
42

Working
1:1000
Cconcentration
1:1000
1:400
1:1000

Caspase-3 activity measurement

Activated caspase-3 in neonatal mouse cardiomyocytes was determined by a caspase-3
activity assay kit according to the manufacturer's protocol (BIOMOL Research
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Laboratories). The cardiomyocytes were lysed with a lysis buffer (Table 15). The cell
lysates were collected and centrifuged at 10,000 g for 10 min at 4 °C. The supernatant was
transferred to a clean tube and the protein concentration was measured by the Bradford
assay as described above. Then, 100 µg of protein supernatant was added to the 96-well
black plate. The equal volumes of assay buffer (Table 15) containing the substrate AcDEVD-AMC (Cayman Chemical Company) or Ac-DEVD-AMC inhibitor AC-DEVDCHO (Cayman Chemical Company) was also added to the plate. The substrate Ac- DEVDAMC was cleaved by caspase-3 and the released chromophore AMC was detected by a
fluorescence spectrophotometer. After that, the plate was incubated at 37 °C for 2 hours
and the fluorescence intensity of cleaved AMC was quantified by a fluorescence
spectrophotometer with excitation of 355 nm and emission of 460 nm. The fluorescence
signals were read every 30 min.
Table 15: Components of Lysis/Assay Buffer (100mL)
HEPES (1 M, pH=7.4)
CHAPS
NaCl
DTT (1 M)
EDTA (0.5 M)
NP-40
Glycerol
H2 O

2.6

Lysis buffer
5 mL
0.1 g
500 µL
20 µL
100 µL
94.4 mL

Assay buffer
5 mL
0.1 g
585 mg
1 mL
200 µL
10 mL
83.8 mL

Cellular DNA fragmentation measurement

DNA fragmentation was detected by a Cellular DNA Fragmentation ELISA kit (Roche
Applied Science) according the manufacturer’s instructions. The neonatal mouse
cardiomyocytes were pre-treated with BrdU labeling reagent for about 20 hours. After
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various treatments, cells were washed with phosphate buffered saline (PBS, Table 16)
twice and lysed with 1X incubation buffer. After incubation for 30 min at room temperature,
the cell lysates were collected and centrifuged at 250 g for 10 min at 4 °C. The supernatant
was collected and its protein concentration was measured by the Bradford assay. A 96-well
plate was pre-coated with 1X anti-DNA antibody at 4 °C overnight. After that, the precoated 96-well plate was blocked with 1X incubation buffer at room temperature for 30
min. Then, the 96-well plate was washed 3 times with 1X washing buffer, 2-3 min each
time. 200 µg of protein supernatant was added into the 96-well plate for 90 min at room
temperature or at 4 °C overnight. In this step, the BrdU-labeled DNA fragments bound to
the immobilized anti-DNA antibody. After that, the supernatants were discarded and the
96-well plate was washed twice, 2-3 min each time. After the third wash, the 96-well plate
with a washing buffer was placed in a microwave at middle power for 5 min. Then, the 96well plate was cooled for 10 min at -20 °C. In this step, BrdU-labeled DNA fragments were
denatured and fixed on the bottom of the 96-well plate. The washing buffer was discarded
and the secondary antibody anti-BrdU-peroxidase was added into the 96-well plate and
incubated at room temperature for 90 min. Similarly, after incubation, the reaction solution
containing the secondary antibody was discarded and the 96-well plate was washed 3 times,
2-3 min each time. Then, the TMB substrate was added to each well and incubated for
about 10 min at room temperature and the reaction was stopped by a stop buffer. Finally,
the absorbance value in the 96-well plate was measured with excitation of 355 nm and
emission of 450 nm.
Table 16: Components of PBS (1L)
NaCl
KCl

8g
0.2 g
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Na2HPO4
KH2PO4

2.7

3.58 g
0.24 g

Oleate/Palmitate (OA/PA) solution preparation

Stock solutions for 20 mM OA and 20 mM PA were prepared as follows. OA (Sigma) and
PA (Sigma) were dissolved in 0.1 M NaOH by heating at 70°C. A 20% bovine serum
albumin (BSA) solution was prepared in H2O. The OA or PA stock solution was mixed
with a 20% BSA solution followed by incubation for 10 min at 55 °C to prepare a 10 mM
OA/PA-10% BSA complex solution. The complex solution was cooled to room
temperature and filtered through a polyethersulfone membrane (pore size 0.1 µm) for
sterilization. The complex solutions were heated for 15 min at 55 °C, then cooled to room
temperature before use.

2.8

Cytoplastic free Ca2+ detection

Neonatal mouse cardiomyocytes were seeded in the 96-well black plate with a transparent
bottom. After various treatments, the cardiomyocytes were ready for staining. Fura-2 was
a Ca2+ imaging dye that binds to free Ca2+. Fura-2 AM was the cell-permeable
acetoxymethyl (AM) ester form of Fura-2. Fura-2 AM (Invitrogen) was diluted in culture
medium (10% NBCS DMEM). The final concentration was 4 µM. Then, Fura-2 AM was
added to the 96-well black plate and incubated at 37 °C for 60 min. The plate was washed
3 times with HBSS (Hank’s balanced salt solution, Gibco) and the fluorescence intensity
(R) in the 96-well black plate was measured by a fluorescence spectrophotometer with
excitation of 340/380 nm and emission of 510 nm. Next, the neonatal cardiomyocytes were
treated with 0.05% Triton-X 100 (Sigma) which was used to release all of the free Ca2+ in
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cardiomyocytes to obtain the maximum fluorescence signal (RTriton-X 100). Similarly, the
fluorescence intensity was detected by a fluorescence spectrophotometer with excitation of
340/380 nm and emission of 510 nm. Then, the cardiomyocytes were treated with 20 mM
EGTA (Bio Basic) to block the free Ca2+ which was applied to acquire the minimum
fluorescence signal （ REGTA ） . The fluorescence intensity was also determined as
described before (157). Finally, the concentration of cytoplastic free Ca2+ was calculated
according to the formula: [ Ca2+]i = Kd × [ (R - REGTA)/(RTriton-X 100 - R) ] × (F380 EGTA/F380
Triton-X 100).

2.9

(Kd = 225 nM, R = F340/F380)

Statistical analysis

All data were presented as mean ± standard deviation (SD). Results were analyzed by oneway or two-way ANOVA as appropriate, followed by Fisher’s LSD test or Newman-Keuls
test for multi-group comparisons. A Student’s t-test was used for comparison between 2
groups. The value P < 0.05 was considered statistically significant.

Table 17: Reagent Information
Name
Taq DNA polymerase
Liberase Blendzyme
DMEM
NBCS
Gelatin
Ad-JPH2
Ad-shJPH2
Ad-GFP
Ad-HA
Bradford assay

Company
FroggaBio (Toronto, Canada)
Roche （Basel, Switzerland）
Wisent Inc （Quebec,Canada）
Gibco （California,America）
Sigma （Missouri, America）
Vector biolabs （Malvern, America）
Vector biolabs（Malvern, America）
SignaGen laboratories （Rockville, America）
Vector biolabs （Malvern, America）
Bio-Rad （California,America）

Cat Number
T-500
05401151001
319010CL
26010-074
G9382
ADV-212592
Customized
SL100708
ADV-294343
500-0001
（Malvern,
America）
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PVDF membrane
Non-fat milk
Tween 20
BSA
Ac-DEVD-AMC
Ac-DEVD-CHO
DNA fragmentation
Oleate
ELISA kit
Palmitate
Fura-2 AM
HBSS
Triton X-100
EGTA
NaOH
EDTA
Tris
HCl
KCl
KH2PO4
NaCl
D-Glucose
Phenol red
SDS
Bromophenol Blue
Glycerol
β-Mercaptoethanol
Acrylamide
APS
TEMED
Glycine
Methanol
Coumeric acid
Luminol
HEPES
CHAPS

Froggabio (Toronto, Canada)
Bio Basic (Toronto, Canada)
Sigma（Missouri, America）
Sigma（Missouri, America）
Cayman Chemical （Michigan, America）
Cayman Chemical （Michigan, America）
Roche （Basel, Switzerland）
Sigma（Missouri, America）
Sigma（Missouri, America）
eBioscience（California,America）
Gibco（California,America）
Sigma（Missouri, America）
Bio Basic (Toronto, Canada)
VWR （Pennsylvania, America）
Sigma（Missouri, America）
Bio Basic (Toronto, Canada)
Sigma（Missouri, America）
Sigma（Missouri, America）
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)
Sigma（Missouri, America）
Sigma（Missouri, America）
Sigma（Missouri, America）
Sigma（Missouri, America）
Sigma（Missouri, America）
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)
VWR（Pennsylvania, America）
Sigma（Missouri, America）
Sigma（Missouri, America）
Bio Basic (Toronto, Canada)
Bio Basic (Toronto, Canada)

TM300
NB0669
P9416
A9647
14986
10017
11585045001
O7501
P9767
65085839
14065056
T9284
ED0077
BDH7222-1
E5134
TB0196
HX0603-4
PX1405-1
PB0445
DB0483
GB0219
P5530
L3771
20017
G5516
444203
AB1032
AB0072
TB 0508
GB0235
BDH1135-4LP
C9008
A8511
HB0264
CD0110
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DTT
NP-40
Na2HPO4
Ryanodine

Bio Basic (Toronto, Canada)
Sigma（Missouri, America）
Sigma（Missouri, America）
Abcam （Cambridge, England）

DB0058
13021
S0876
ab120083
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Chapter 3

3

Results

3.1

Palmitate incubation increases caspase-3 activity in cultured
neonatal mouse cardiomyocytes

It was reported that palmitate was able to cause apoptosis in cardiomyocytes (158-161). To
confirm this finding in our study, neonatal mouse cardiomyocytes were treated with
palmitate (PA), a main saturated free fatty acid in western diet, and oleate (OA) served as
a control. Palmitate has been widely applied in the study of cardiac lipotoxicity. Most of
the studies show that the concentration of palmitate ranges from 100 µM to 1200 µM (162168). We tried 200 µM, 400 µM and 800 µM palmitate to treat neonatal cardiomyocytes
and found the concentration of 800 µM showed the best induction of apoptosis in
cardiomyocytes compared to oleate. Since then, we used this concentration of palmitate for
the following studies. Neonatal mouse cardiomyocytes were treated with PA (800 µM) or
OA (800 µM) for 48 hours. Then, caspase-3 activity was measured to indicate the apoptosis
in cardiomyocytes. Palmitate incubation increased caspase-3 activity by 60% in neonatal
cardiomyocytes compared to OA group (Figure 3).
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Figure 3: Palmitate incubation increases caspase-3 activity in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) for 48 hours, the apoptosis in
neonatal mouse cardiomyocytes was analyzed by the measurement of caspase-3
activity. Data was mean ± SD from 4 independent experiments and analyzed by
unpaired Student’s t-test. * P < 0.05 versus OA.

39

3.2

Palmitate incubation increases DNA fragmentation in cultured
neonatal mouse cardiomyocytes

Neonatal mouse cardiomyocytes were treated with PA (800 µM) or OA (800 µM) for 48
hours. Then, DNA fragmentation was measured to indicate the apoptosis in
cardiomyocytes. PA incubation increased DNA fragmentation by 50% in neonatal
cardiomyocytes relative to OA group (Figure 4). These results (Figure 3 and 4) confirmed
that palmitate incubation induces apoptosis in cultured neonatal mouse cardiomyocytes
when compared to oleate.
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Figure 4: Palmitate incubation increases DNA fragmentation in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) for 48 hours, the apoptosis in
neonatal mouse cardiomyocytes was analyzed by the measurement of DNA
fragmentation. Data was mean ± SD from 3 independent experiments and analyzed
by unpaired Student’s t-test. * P < 0.05 versus OA.
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3.3

Palmitate incubation reduces JPH2 expression in cultured
neonatal mouse cardiomyocytes

The expression of JPH2 was down-regulated in many cardiac diseases (35, 36). Prior study
from our lab showed that the protein levels of JPH2 were reduced in the hearts of mice fed
with high fat diet for 4 months (2). To confirm this, neonatal mouse cardiomyocytes were
treated with 800 uM PA or OA for 48 hours. The protein levels of JPH2 were determined
by western blot analysis. PA incubation decreased JPH2 expression by 30% in neonatal
mouse cardiomyocytes compared to OA group (Figure 5). This result indicated that
palmitate incubation reduces JPH2 expression in neonatal mouse cardiomyocytes when
compared to oleate.
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Figure 5: Palmitate incubation reduces JPH2 protein expression in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) for 48 hours, the protein levels of
JPH2 were analyzed by western blot analysis. GAPDH was used as a loading
control. Upper panel: a representative western blot for JPH2 and GAPDH from 4
different cultures with each in duplicate; lower panel: quantitation of the protein
levels of JPH2 relative to GAPDH. Data was mean ± SD from 4 independent
experiments and analyzed by unpaired Student’s t-test. * P < 0.05 versus OA.
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3.4

Knockdown

of

JPH2

in

cultured

neonatal

mouse

cardiomyocytes
To study the influence of JPH2 down-regulation in neonatal mouse cardiomyocytes, we
used an adenoviral vector containing shJPH2 (Ad-shJPH2) to knock down JPH2. An
adenoviral vector containing GFP (Ad-GFP) served as a control. Neonatal mouse
cardiomyocytes were infected with Ad-shJPH2 (30, 60 or 100 PFU/cell) or Ad-GFP (100
PFU/cell). 48 hours later, the protein levels of JPH2 were determined by western blot
analysis. The protein levels of JPH2 were reduced in cardiomyocytes infected with AdshJPH2 compared to Ad-GFP group by 30%, 60% and 80% (Figure 6). This result
indicated a successful knowdown of JPH2 by Ad-shJPH2 in cardiomyocytes. Since the
dose of 100 PFU/cell showed the best knowdown of JPH2, we used this dose of Ad-shJPH2
for the following studies.
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Figure 6: Knockdown of JPH2 with Ad-shJPH2 in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. The cells
were infected with Ad-shJPH2 or Ad-GFP. 48 hours later, the protein levels of
JPH2 in neonatal cardiomyocytes were analyzed by western blot. Actin was used
as a loading control. Upper panel: a representative western blot for JPH2 and Actin
from 3 different cultures with each in duplicate. Lower panel: quantitation of the
protein levels of JPH2 relative to Actin. Data was mean ± SD from 3 independent
experiments, and analyzed by one-way ANOVA followed by Fisher’s LSD test.
* P < 0.05 versus Ad-GFP.
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3.5

JPH2 knockdown enhances palmitate-induced caspase-3
activity in cultured neonatal mouse cardiomyocytes

To investigate whether JPH2 knockdown enhanced palmitate-induced cardiomyocyte
injury, we knocked down JPH2 in cardiomyocytes and treated the cardiomyocytes with PA.
Neonatal mouse cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP
(100 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours.
The caspase-3 activity was measured to indicate apoptosis. Knockdown of JPH2 solely
induced higher caspase-3 activity by 330% compared to the Ad-GFP group, indicating
apoptotic cell death. Similarly, treatment with PA solely also resulted in higher caspase-3
activity by 100% compared with OA group. Furthermore, palmitate-induced apoptosis was
enhanced by knockdown of JPH2 by 160% as determined by caspase-3 activity (Figure 7).
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Figure 7: JPH2 knockdown enhances palmitate-induced caspase-3 activity in
neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP, together with incubation with oleate (OA)
or palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was
analyzed by the measurement of caspase-3 activity. Data was mean ± SD from 5
independent experiments and analyzed by two-way ANOVA followed by
Newman-Keuls test. * P < 0.05 versus OA-Ad-GFP, # P < 0.05 versus PA-Ad-GFP.
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3.6 JPH2

knockdown

enhances

palmitate-induced

DNA

fragmentation in cultured neonatal mouse cardiomyocytes
Neonatal mouse cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP
(100 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours.
DNA fragmentation was measured to indicate the apoptosis. Knockdown of JPH2 solely
induced greater DNA fragmentation by 100% compared to Ad-GFP group, indicating
apoptotic cell death. Similarly, treatment of PA solely also induced greater DNA
fragmentation by 40% compared to OA group. Furthermore, palmitate-induced apoptosis
was exacerbated by JPH2 knockdown by 65% as measured by DNA fragmentation (Figure
8). These results (Figure 7 and 8) demonstrated that JPH2 knockdown enhances palmitateinduced apoptosis in neonatal cardiomyocytes.
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Figure 8: JPH2 knockdown enhances palmitate-induced DNA fragmentation in
neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP, together with incubation with oleate (OA)
or palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was
analyzed by the measurement of DNA fragmentation. Data was mean ± SD from
3 independent experiments and analyzed by two-way ANOVA followed by
Newman Keuls test. * P < 0.05 versus OA-Ad-GFP, # P < 0.05 versus PA-Ad-GFP.
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3.7

Over-expression of JPH2 in cultured neonatal mouse
cardiomyocytes

To up-regulate JPH2 expression, we used an adenoviral vector containing JPH2 (Ad-JPH2).
An adenoviral vector containing human influenza hemagglutinin (aa 98-106) peptide tag
(Ad-HA) served as a control. Neonatal mouse cardiomyocytes were infected with Ad-JPH2
(10, 20 and 40 PFU/cell) or Ad-HA (40 PFU/cell). 48 hours later, the protein levels of
JPH2 were determined by western blot analysis. The protein levels of JPH2 were higher
by 40%, 200% and 300% in cardiomyocytes infected with Ad-JPH2 compared to Ad-HA
group (Figure 9). This result indicated a successful over-expression of JPH2 by Ad-JPH2
in cardiomyocytes. Since the dose of 40 PFU/cell showed the best over-expression of JPH2,
we used this dose of Ad-JPH2 for the following studies.
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Figure 9: Over-expression of JPH2 with Ad-JPH2 in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-JPH2 or Ad-HA for 48 hours, the protein levels of JPH2 in
neonatal cardiomyocytes were analyzed by western blot. Actin was used as a
loading control. Upper panel: a representative western blot for JPH2 and Actin from
3 different cultures, each in duplicate. Lower panel: quantitation of the protein
levels of JPH2 relative to Actin. Data was mean ± SD from 3 independent
experiments and analyzed by one-way ANOVA followed by Fisher’s LSD test.
* P < 0.05 versus Ad-HA.
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3.8

JPH2 over-expression attenuates palmitate-induced caspase-3
activity in cultured neonatal mouse cardiomyocytes

To determine whether JPH2 over-expression had a protective role in palmitate-induced cell
injury, we over-expressed JPH2 in cardiomyocytes and treated the cardiomyocytes with
PA. Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or AdHA (40 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24
hours. Caspase-3 activity was measured to indicate the apoptosis. JPH2 over-expression
solely reduced caspase-3 activity by 60% compared to Ad-HA group. PA treatment
resulted in greater caspase-3 activity by 50% in neonatal cardiomyocytes compared to OA
group, indicative of apoptotic cell death. However, PA-induced caspase-3 activity was
attenuated by the over-expression of JPH2 by 60% in neonatal cardiomyocytes (Figure 10).
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Figure 10: JPH2 over-expression attenuates palmitate-induced caspase-3 activity in
neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or
palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was
analyzed by the measurement of caspase-3 activity. Data was mean ± SD from 4
independent experiments and analyzed by two-way ANOVA followed by
Newman-Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA.
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3.9

JPH2 over-expression attenuates palmitate-induced DNA
fragmentation in cultured neonatal mouse cardiomyocytes

Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-HA (40
PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24 hours. DNA
fragmentation was further measured to indicate the apoptosis. JPH2 over-expression solely
reduced DNA fragmentation by 50% compared to Ad-HA group.PA treatment resulted in
greater DNA fragmentation by 50% in neonatal cardiomyocytes relative to OA group,
indicating of apoptotic cell death. In contrast, PA-induced DNA fragmentation was
attenuated by the over-expression of JPH2 by 50% in neonatal cardiomyocytes (Figure 11).
These results (Figure 10 and 11) indicated that JPH2 over-expression attenuates palmitateinduced apoptosis in neonatal cardiomyocytes.
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Figure 11: JPH2 over-expression attenuates palmitate-induced DNA fragmentation
in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or
palmitate (PA) for 48 hours, apoptosis in neonatal mouse cardiomyocytes was
analyzed by the measurement of DNA fragmentation. Data was mean ± SD from 3
independent experiments and analyzed by two-way ANOVA followed by Newman
Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA.
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3.10 Knockdown of JPH2 induces caspase-3 activity in cultured
neonatal mouse cardiomyocytes
We had successfully knocked down JPH2 by Ad-shJPH2 in neonatal mouse
cardiomyocytes. Next, we wanted to determine whether JPH2 knockdown sufficiently
induced apoptosis in cardiomyocytes. Similarly, we used Ad-shJPH2 to knockdown JPH2
and Ad-GFP served as a control. Neonatal cardiomyocytes were infected with Ad-shJPH2
(100 PFU/cell) or Ad-GFP (100 PFU/cell) for 48 hours. Apoptosis was assessed by
measuring caspase-3 activity which was the most frequently activated death protease in the
execution phase of apoptosis. JPH2 knockdown resulted in greater caspase-3 activity by
210% in neonatal cardiomyocytes infected with Ad-shJPH2 compared to Ad-GFP group
(Figure 12).

56

Figure 12: JPH2 knockdown induces caspase-3 activity in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP for 48 hours, apoptosis in neonatal mouse
cardiomyocytes was determined by the detection of caspase-3 activity. Data was
mean ± SD from 4 independent experiments and analyzed by unpaired Student’s ttest. * P < 0.05 versus Ad-GFP.
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3.11 Knockdown of JPH2 increases DNA fragmentation in cultured
neonatal mouse cardiomyocytes
Neonatal cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100
PFU/cell) for 48 hours. Apoptosis was further analyzed by measuring DNA fragmentation,
which was also a biological hallmark of apoptosis. JPH2 knockdown resulted in greater
DNA fragmentation by 90% in neonatal cardiomyocytes infected with Ad-shJPH2
compared to Ad-GFP group (Figure 13). These results (Figure 12 and 13) demonstrated
that knockdown of JPH2 sufficiently induces apoptosis in cultured neonatal mouse
cardiomyocytes relative to Ad-GFP group.
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Figure 13: JPH2 knockdown induces DNA fragmentation in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP for 48 hours, apoptosis in neonatal mouse
cardiomyocytes was determined by the detection of DNA fragmentation. Data was
mean ± SD from 3 independent experiments and analyzed by unpaired Student’s ttest. * P < 0.05 versus Ad-GFP.
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3.12 Palmitate incubation increases CHOP expression in cultured
neonatal mouse cardiomyocytes
To investigate whether palmitate incubation induced ER stress in cardiomyocytes, neonatal
mouse cardiomyocytes were subjected to palmitate incubation. Neonatal mouse
cardiomyocytes were treated with 800 µM PA or OA for 24 hours. The protein levels of
CHOP were determined by western blot as an indicator of ER stress. Similarly, PA
treatment also induced higher CHOP expression by 120% in neonatal cardiomyocytes
compared to OA group (Figure 14). This result demonstrated that palmitate incubation
results in higher CHOP expression, indicating palmitate incubation induces ER stress in
neonatal cardiomyocytes compared to oleate.
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Figure 14: Palmitate incubation increases CHOP protein expression in neonatal
mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) for 24 hours, the protein levels of
CHOP were analyzed by western blot. Actin was used as a loading control. Upper
panel: a representative western blot for CHOP and actin from 4 different cultures
in duplicate. Lower panel: quantitation of the protein levels of CHOP relative to
actin. Data was mean ± SD from 4 independent experiments and analyzed by
unpaired Student’s t-test. * P < 0.05 versus OA.

61

3.13 JPH2 knockdown increases CHOP expression in cultured
neonatal mouse cardiomyocytes
To determine whether JPH2 knockdown induced ER stress in cardiomyocytes, neonatal
mouse cardiomyocytes were subjected to Ad-shJPH2 infection. Neonatal mouse
cardiomyocytes were infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100 PFU/cell)
for 24 hours. CHOP was detected to indicate the ER stress in neonatal cardiomyocytes.
The protein levels of CHOP were determined by western blot. JPH2 knockdown resulted
in higher CHOP expression by 60% in neonatal cardiomyocytes compared to Ad-GFP
group (Figure 15).

62

Figure 15: JPH2 knockdown increases CHOP protein expression in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-GFP/Ad-shJPH2 for 24 hours, the protein levels of CHOP were
analyzed by western blot. Actin was used as a loading control. Upper panel: a
representative western blot for CHOP and actin from 4 different cultures with each
in duplicate. Lower panel: quantitation of the protein levels of CHOP relative to
actin. Data was mean ± SD from 4 independent experiments and analyzed by
unpaired Student’s t-test. * P < 0.05 versus Ad-GFP.

63

3.14 Over-expression of JPH2 attenuates palmitate-induced CHOP
expression in cultured neonatal mouse cardiomyocytes
We had shown that both JPH2 knockdown and palmitate incubation induced ER stress and
apoptosis in cardiomyocytes, and over-expression of JPH2 protected cardiomyocytes
against palmitate-induced apoptosis. Therefore, we were curious whether this protective
role of JPH2 was dependent on preventing ER stress. To investigate if JPH2 overexpression attenuated palmitate-induced ER stress in cardiomyocytes, we over-expressed
JPH2 in neonatal cardiomyocytes first and then treated the cardiomyocytes with palmitate.
Neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or Ad-HA (40
PFU/cell) for 24 hours. Then, the cardiomyocytes were treated with 800 µM PA or OA for
24 hours. CHOP expression was detected to indicate the ER stress in neonatal
cardiomyocytes. The protein levels of CHOP were determined by western blot. PA
treatment resulted in greater CHOP expression by 260% in cardiomyocytes compared to
OA group, indicating of ER stress. JPH2 over-expression prevented palmitate-induced
CHOP expression by 40% in neonatal cardiomyocytes (Figure 16). This result indicated
that JPH2 over-expression attenuates palmitate-induced ER stress in neonatal
cardiomyocytes.
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Figure 16: JPH2 over-expression attenuates palmitate-induced CHOP protein
expression in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-JPH2 or Ad-HA and incubation with oleate (OA) or palmitate
(PA), the protein levels of CHOP were analyzed by western blot. GAPDH was used
as a loading control. Upper panel: a representative western blot for CHOP and
GAPDH from 3 different cultures in duplicate. Lower panel: quantitation of the
protein levels of CHOP relative to GAPDH. Data was mean ± SD from 3
independent experiments and analyzed by two-way ANOVA followed by
Newman-Keuls test. * P < 0.05 versus OA-Ad-HA, # P < 0.05 versus PA-Ad-HA.
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3.15 CHOP knockout reduces JPH2 knockdown-induced caspase-3
activity in cultured neonatal mouse cardiomyocytes
To determine if JPH2 knockdown induced apoptosis by CHOP up-regulation in
cardiomyocytes, we isolated neonatal cardiomyocytes from wild type (WT) or CHOP
knockout (CHOP-/-) mice. Neonatal mouse cardiomyocytes from WT/CHOP-/- mice were
infected with Ad-shJPH2 (100 PFU/cell) or Ad-GFP (100 PFU/cell) for 48 hours. Then,
caspase-3 activity was measured to indicate apoptosis in cardiomyocytes. As observed
earlier, JPH2 knockdown resulted in greater caspase-3 activity by 210% in WT
cardiomyocytes (Figure 17). CHOP knockout resulted in lower JPH2 knockdown-induced
caspase-3 activity by 15% in neonatal cardiomyocytes (Figure 17).
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Figure 17: CHOP knockout reduces JPH2 knockdown-induced caspase-3 activity in
neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP for 48 hours, caspase-3 activity was analyzed
in neonatal mouse cardiomyocytes from WT/CHOP-/- mice. Data was mean ± SD from
8 independent experiments and analyzed by two-way ANOVA followed by Newman
Keuls test. * P < 0.05 versus Ad-GFP-WT, # P < 0.05 versus Ad-shJPH2-WT.

67

3.16 CHOP knockout reduces palmitate-induced caspase-3 activity
in cultured neonatal mouse cardiomyocytes
To determine if palmitate induced apoptosis through CHOP up-regulation in
cardiomyocytes, we isolated neonatal cardiomyocytes from wild type (WT) or CHOP
knockout (CHOP-/-) mice. Neonatal cardiomyocytes from WT/CHOP-/- mice were treated
with 800 µM PA or OA for 48 hours. Then, caspase-3 activity was measured to indicate
apoptosis in cardiomyocytes. CHOP knockout solely reduced caspase-3 activity by 40%
compared to WT cardiomyocytes. PA incubation resulted in greater caspase-3 activity by
70% in WT cardiomyocytes when compared to oleate (Figure 18). CHOP knockout
attenuated palmitate-induced caspase-3 activity by 40% in neonatal cardiomyocytes
(Figure 18). These results (Figure 17 and 18) indicated that CHOP knockout reduces JPH2
knockdown or palmitate-induced caspase-3 activity, indicating CHOP induction is an
important factor contributing to apoptosis caused by JPH2 knockdown or palmitate
incubation.
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Figure 18: CHOP knockout reduces palmitate-induced caspase-3 activity in neonatal
mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) for 48 hours, caspase-3 activity was
determined in neonatal cardiomyocytes from WT/CHOP-/- mice. Data was mean ±
SD from 8 independent experiments and analyzed by two-way ANOVA followed
by Newman Keuls test. * P < 0.05 versus OA-WT, # P < 0.05 versus PA-WT.
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3.17 Inhibition of Ca2+ release from RyR2 reduces palmitateinduced CHOP expression in cultured neonatal mouse
cardiomyocytes
To determine whether palmitate induced CHOP expression through Ca2+ release from
RyR2, we used ryanodine to block Ca2+ release from RyR2 in cardiomyocytes. To do this,
neonatal cardiomyocytes were treated with 800 µM PA or OA for 24 hours together with
incubation with ryanodine (0, 10 and 50 µM). The protein levels of CHOP were determined
by western blot to indicate ER stress. Palmitate incubation resulted in greater expression
of CHOP by 100% in cardiomyocytes when compared to oleate (Figure 19). Ryanodine
resulted in lower palmitate-induced CHOP expression by 30% and 50% in neonatal
cardiomyocytes (Figure 19). These results demonstrated that inhibition of Ca2+ release
from RyR2 prevents palmitate incubation-induced CHOP expression, indicating disruption
of Ca2+ homeostasis participates in palmitate incubation-induced ER stress in
cardiomyocytes.
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Figure 19: Inhibition of Ca2+ release from RyR2 reduces palmitate-induced CHOP
protein expression in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment
for 24 hours, the protein levels of CHOP were analyzed by western blot analysis.
GAPDH was used as a loading control. Upper panel: a representative western blot
for CHOP and GAPDH from 4 different cultures in duplicate. Lower panel:
quantitation of the protein levels of CHOP relative to GAPDH. Data was mean ±
SD from 4 independent experiments and analyzed by two-way ANOVA followed
by Newman-Keuls test. * P < 0.05 versus OA-0 µM ryanodine, # P < 0.05 versus
PA-0 µM ryanodine.
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3.18 Inhibition of Ca2+ release from RyR2 reduces JPH2
knockdown-induced CHOP expression in cultured neonatal
mouse cardiomyocytes
To determine if JPH2 knockdown induced CHOP expression through Ca2+ release from
RyR2 in cardiomyocytes, neonatal mouse cardiomyocytes were infected with Ad-shJPH2
(100 PFU/cell) or Ad-GFP (100 PFU/cell) for 24 hours. At the same time, neonatal
cardiomyocytes were treated with ryanodine (0, 10 and 50 µM). The protein levels of
CHOP were determined by western blot to indicate ER stress. JPH2 knockdown resulted
in greater expression of CHOP by 40% in cardiomyocytes (Figure 20). Ryanodine resulted
in lower JPH2 knockdown-induced CHOP expression by 25% and 70% in neonatal
cardiomyocytes (Figure 20).
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Figure 20: Inhibition of Ca2+ release from RyR2 reduces JPH2 knockdown-induced
CHOP protein expression in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-shJPH2 or Ad-GFP with or without ryanodine incubation for 24
hours, the protein levels of CHOP were analyzed by western blot. GAPDH was
used as a loading control. Upper panel: a representative western blot for CHOP and
GAPDH from 4 different cultures in duplicate. Lower panel: quantitation of the
protein levels of CHOP relative to GAPDH. Data was mean ± SD from 4
independent experiments and analyzed by two-way ANOVA followed by
Newman-Keuls test. * P < 0.05 versus Ad-GFP-0 µM ryanodine, # P < 0.05 versus
Ad-shJPH2-0 µM ryanodine.
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3.19 Inhibition of Ca2+ release from RyR2 reduces palmitateinduced apoptosis in cultured neonatal mouse cardiomyocytes
Since inhibition of Ca2+ release from RyR2 by ryanodine reduced palmitate-induced ER
stress in cardiomyocytes, we next investigated if ryanodine decreased palmitate-induced
apoptosis. Neonatal mouse cardiomyocytes were incubated with 800 µM OA or PA for 48
hours. At the same time, the cardiomyocytes were treated with or without 50 µM ryanodine.
Caspase-3 activity was detected to indicate apoptosis in neonatal cardiomyocytes. PA
incubation resulted in greater caspase-3 activity by 80% in cardiomyocytes compared to
OA group. Ryanodine resulted in lower palmitate-induced caspase-3 activity by 30% in
neonatal cardiomyocytes (Figure 21). This result demonstrated that inhibition of Ca2+
release from RyR2 reduces palmitate-induced apoptosis in cardiomyocytes.
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Figure 21: Inhibition of Ca2+ release from RyR2 reduces palmitate-induced caspase3 activity in neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment
for 48 hours, caspase-3 activity was analyzed in neonatal mouse cardiomyocytes.
Data was mean ± SD from 8 independent experiments and analyzed by two-way
ANOVA followed by Newman-Keuls test. * P < 0.05 versus OA-Vehicle, # P <
0.05 versus PA-Vehicle.
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3.20 Ryanodine reduces palmitate-induced Ca2+ release in cultured
neonatal mouse cardiomyocytes
Since disruption of Ca2+ homeostasis contributed to ER stress and apoptosis in
cardiomyocytes (76), we next determined the cytoplasmic free Ca2+ level to further
investigate if Ca2+ imbalance participated in palmitate-induced cardiomyocyte injury.
Neonatal mouse cardiomyocytes were incubated with 800 µM OA or PA for 48 hours. At
the same time, the cardiomyocytes were treated with or without 50 µM ryanodine. Fura-2
AM was used to stain cytoplasmic free Ca2+ in cardiomyocytes. Ryanodine was
administrated to inhibit Ca2+ release from RyR2 in cardiomyocytes. PA incubation resulted
in greater cytoplasmic free Ca2+ by 160% in cardiomyocytes compared to OA group.
Ryanodine resulted in lower palmitate-induced cytoplasmic free Ca2+ by 50% in neonatal
cardiomyocytes (Figure 22). This result demonstrated that palmitate incubation induces
excessive Ca2+ release and ryanodine reduces palmitate-induced Ca2+ release in
cardiomyocytes.
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Figure 22 Ryanodine reduces palmitate-induced Ca2+ release in neonatal mouse
cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
incubation with oleate (OA) or palmitate (PA) with or without ryanodine treatment
for 48 hours, cytoplasmic free Ca2+ was analyzed in neonatal mouse
cardiomyocytes. Data was mean ± SD from 4 independent experiments and
analyzed by two-way ANOVA followed by Newman-Keuls test. * P < 0.05 versus
OA-Vehicle, # P < 0.05 versus PA-Vehicle.
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3.21 JPH2 over-expression attenuates palmitate-induced Ca2+
release in cultured neonatal mouse cardiomyocytes
As mentioned before, JPH2 protected cardiomyocytes against palmitate-induced injury by
preventing ER stress and subsequent apoptosis. Palmitate incubation increased cytoplasmic
free Ca2+ relative to oleate, contributing to ER stress and apoptosis in cardiomyocytes. We
hypothesized that JPH2 protected cardiomyocytes against palmitate-induced ER stress and
apoptosis through preventing excessive Ca2+ release in cardiomyocytes. To demonstrate
this, neonatal mouse cardiomyocytes were infected with Ad-JPH2 (40 PFU/cell) or AdHA (40 PFU/cell) for 24 hours and then treated with 800 µM PA or OA for another 24
hours. Fura-2 AM was used to stain cytoplasmic free Ca2+ in cardiomyocytes. PA
incubation resulted in greater cytoplasmic free Ca2+ by 100% in cardiomyocytes compared
to OA group. JPH2 over-expression resulted in lower palmitate-induced cytoplasmic free
Ca2+ by 45% in neonatal cardiomyocytes (Figure 23). This result demonstrated that JPH2
over-expression attenuates palmitate-induced Ca2+ release in cardiomyocytes.
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Figure 23 JPH2 over-expression attenuates palmitate-induced Ca2+ release in
neonatal mouse cardiomyocytes.
Neonatal mouse cardiomyocytes were isolated and cultured for 24 hours. After
infection with Ad-JPH2 or Ad-HA, together with incubation with oleate (OA) or
palmitate (PA) for 48 hours, cytoplasmic free Ca2+ was analyzed in neonatal mouse
cardiomyocytes. Data was mean ± SD from 4 independent experiments and
analyzed by two-way ANOVA followed by Newman-Keuls test. * P < 0.05 versus
OA-Ad-HA, # P < 0.05 versus PA-Ad-HA.
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Chapter 4

4

Discussion, Limitations and Future Directions

4.1

Discussion

The major findings of this study are that silencing of JPH2 enhances, whereas overexpression of JPH2 reduces palmitate-induced apoptosis in cardiomyocytes. Also, overexpression of JPH2 attenuates palmitate-induced CHOP expression and apoptosis while
deletion of CHOP pevents apoptosis in palmitate-stimulated cardiomyocytes. Furthermore,
over-expression of JPH2 lowers the levels of cytosolic free Ca2+ and blockage of Ca2+
release from RyR2 with ryanodine reduces the levels of CHOP protein and inhibits
apoptosis in palmitate-stimulated cardiomyocytes. Additionally, silencing of JPH2
sufficiently induces CHOP expression, increases cytosolic free Ca2+ and elicits apoptosis
in cardiomyocytes. These effects of JPH2 knockdown are prevented by CHOP deletion and
blockage of Ca2+ release from RyR2. Thus, our study reveals a novel protection of JPH2
against palmitate-induced apoptosis in cardiomoycytes.

4.1.1 Palmitate-mediated down-regulation of JPH2 in cardiomyocytes
A reduction of JPH2 protein has been reported in human diseased hearts including dilated
cardiomyopathy, hypotrophy and heart failure (36, 43, 169, 170). JPH2 down-regulation
has also been found in mouse models of heart diseases (53, 58, 171). Studies from our lab
showed that the protein levels of JPH2 were decreased in high fat diet-fed mouse hearts
and that in cultured neonatal cardiomoycytes and incubation with palmitate led to a
reduction of JPH2 protein levels when compared to oleate (2). Consistent with this prior
report, the present study also shows that palmitate incubation reduces the protein levels of
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JPH2 in cultured neonatal cardiomyocytes when compared to oleate. These studies suggest
that JPH2 expression may be altered in cardiomyocytes with metabolic disorders. Although
palmitate represents an important saturated free fatty acid in western diets, which
contributes to cardiac lipotoxic injury in metabolic disorders (28), there are other important
dietary saturated free fatty acids such as myristic acid and stearic acid. It remains to be
determined if these other saturated free fatty acids also induce down-regulation of JPH2 in
cardiomyocytes. In addition, it is unknown whether high glucose plays a role in the
regulation of JPH2 in cardiomyocytes. Currently, we do not know how palmitate causes
down-regulation of JPH2 protein in cardiomyocytes. A prior study showed that inhibition
of calpain increased the protein levels of JPH2 in palmitate-stimulated cardiomyocytes and
high fat diet-fed mouse hearts (2), underscoring an important role of calpain activation in
down-regulation of JPH2. Indeed, it has been reported that calpain directly cleaves JPH2
protein at the site of R565T in the C-terminal of JPH2 (172), leading to down-regulation
of JPH2 during myocardial ischemia/reperfusion injury. In addition to calpain activation,
alternative mechanisms have also been reported to be contributed to dysregulation of JPH2
in the heart under stress. First, it is shown that up-regulated miR-24 is correlated with JPH2
down-regulation in human diseased hearts and that inhibition of miR-24 restores JPH2
expression in mouse model of cardiac hypertrophy (48). Mechanistic study reveals that
miR-24 targets and represses JPH2 protein translation through a binding site in the 3’terminal of JPH2 mRNA (48). Second, it is reported that JPH2 is the target of miR-34a in
diseased hearts (173). Third, a very recent study shows that MMP-2 directly cleaves and
down-regulates JPH2 protein in cardiomyocytes following ischemia/reperfusion injury
(57). We currently do not know whether these alternative mechanisms are involved in the
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palmitate-induced down-regulation of JPH2 protein in cardiomyocytes, but it is possible
that they may contribute to JPH2 protein down-regulation as miR-24, miR-34a and MMP2 have been reported to increase in hearts with metabolic disorders (48, 51, 57, 173).
It is important to point out that the mechanisms mentioned above account for posttranscriptional and post-translational regulation. The transcription regulatory mechanism
responsible for JPH2 mRNA expression has never been demonstrated. It is currently
unknown whether the transcriptional mechanism is involved; however, it merits further
investigation for calrification.

4.1.2 Novel cardiac protection of JPH2 against palmitate-induced apoptosis
JPH2 is an important structural protein in forming junctional membrane complexes (JMCs),
essential for excitation-contraction coupling within cardiomyocytes (36). It is clear that
JPH2 is important in anchoring junctional sarcoplasmic reticulum and transverse-tubule
(T-tubule) membrane invaginations (34). Additionally, JPH2 is also necessary for the
development of postnatal T-tubules in mammals (174). Recent studies have found that
JPH2 plays a critical role in maintaining the complex JMC architecture and stabilizing local
ion channels in mature cardiomyocytes (39). Loss of JPH2’s function by mutations or
down-regulation of its protein expression is associated with hypertrophic cardiomyopathy,
arrhythmias, and the progression of heart failure (31, 35, 43).
The present study reveals an unrecognized role of JPH2 in protecting cardiomyocytes
against palmitate-induced apoptosis. Several lines of evidences support this conclusion.
First, a reduction of JPH2 protein is associated with occurrence of apoptosis in
cardiomyocytes in response to palmitate when compared to oleate. Second, overexpression of JPH2 attenuates whereas silencing of JPH2 enhances palmitate-induced
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apoptosis in cardiomyocytes. Third, silencing of JPH2 induces apoptosis in
cardiomyocytes. This also suggests that JPH2 is necessary for cardiomyocyte survival.
Thus, this study provides additional evidence in support of cardio-protection by JPH2. Our
findings together with a previous report (2) suggest that targeting JPH2 may be an effective
strategy to prevent/treat cardiac injury under stress.

4.1.3 JPH2 prevention of ER stress in cardiomyocytes during lipotoxicity
Palmitate has been linked to ER stress contributing to cell death via apoptosis in
cardiomyocytes (27, 28). In line with this, the present stduy shows that palmitate induces
CHOP protein expression in cardiomyocytes, indicative of ER stress. Interestingly, the
induction of CHOP is associated with a reduction of JPH2 in palmitate-stimulated
cardiomyocytes. Importantly, over-expression of JPH2 prevents palmitate-induced CHOP
expression in cardiomoycytes. These findings suggest that JPH2 suppresses the induction
of ER stress in palmitate-stimulated cardiomyocytes. This is further supported by
additional experimental evidence which shows that silencing of JPH2 induces CHOP
expression in cardiomoycytes.
Since our present data has shown that JPH2 protects cardiomyocytes against palmitateinduced apoptosis, it is reasonable to suspest that the role of JPH2 is mediated through
prevention of CHOP induction. Indeed, deletion of CHOP attenuates both palmitate- and
JPH2 knockdown-induced apoptosis in cardiomyocytes. Thus, we argue that palmitate
leads to a reduction of JPH2, which mediates CHOP induction, leading to apoptosis in
cardiomyocytes.
However, we currently do not know the mechanisms by which a reduction of JPH2 induces
ER stress or CHOP expression in cardiomyocytes. It is well known that ER stress can be
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caused by oxidative stress, ischemia, disturbance of Ca2+ homeostasis etc. (77, 175-179).
We know that JPH2 keeps proper Ca2+-induced Ca2+ release in cardiomyocytes. Of note,
recent studies have demonstrated a role of JPH2 in stabilizing RyR2 (43, 180), which gates
the release of Ca2+ from ER/SR into the cytosol, suggesting that JPH2 may function as a
brake on Ca2+ release from RyR2 as the loss of JPH2 results in aberrant Ca2+ leakage from
the SR through RyR2 (181). Thus, it is most likely that a reduction of JPH2 may lead to
more Ca2+ release from RyR2 into the cytosol, resulting in an elevation of free Ca2+, which
contributes to apoptosis in palmitate-stimulated cardiomyocytes. In line with this, we
shows that palmitate or silencing of JPH2 elevates the levels of free Ca2+ in the cytosol,
and that over-expression of JPH2 decreases the levels of free Ca2+ in the cytosol in
palmitate-stimulated cardiomyocytes. Furthermore, blocking Ca2+ release from RyR2
attenuates CHOP expression and apoptosis induced by palmitate and silencing of JPH2 in
cardiomyocytes. Nevertheless, it remains to be determined how JPH2 stabilizes RyR2 in
controlling Ca2+ release in cardiomyocytes.
On the other hand, an elevation of cytosolic Ca2+ may result from dysfunction of the
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump and/or Na+-Ca2+ exchanger
(NCX) as the former pumps Ca2+ into ER/SR and the latter exports Ca2+ outside of
cardiomyocytes (75). Both are compromised in cardiomyocytes during metabolic disorders
(181-185). Interestingly, studies have shown that JPH2 regulates NCX participating in
regulation of Ca2+ homeostasis in cardiomyocytes (181). Future studies are needed to
determine whether this is also operative in palmitate-stimulated cardiomyocytes.
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4.1.4 Concluding remarks
We have provided evidence that demonstartes an unrecognized role of JPH2 in
cardiomyocytes in prevention of apoptosis induced by palmitate. This new role of JPH2
may be mediated through attenuation of Ca2+ release from RyR2 and subsequent CHOP
expression (also see Figure 24). Given that palmitate has been widely used to induce
lipotoxicity in cardiomyocytes, targeting JPH2 may represent a new therapeutic strategy to
reduce cardiac injury in lipotoxicity.

Figure 24: Summary of findings.
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4.2

Limitations and future directions

We used oleate as a control for palmitate. It is better to include the non-treated control and
investigate whether oleate palys any roles in cardiomyocytes. However, previous studies
have shown that oleate does not have any effects on apoptosis and junctophilin-2
expression in cardiomyocytes.
The present study is focused on isolated neonatal mouse cardiomyocytes. However, the
role of JPH2 in lipotocixity induced cell injury in vivo remains unknown. High fat diet
mouse model will be established to investigate whether JPH2 plays a protective role in
vivo.
Although our recent study showed that deletion of calpain attenuated the reduction of JPH2
in palmitate-stimulated cardiomyocytes and mice fed with HFD, we can not exclude other
mechanisms contributing to JPH2 down-regulation such as through miR-24, miR-34a and
MMP2, which may be examined in future studies.
Future studies are also needed to determine how JPH2 modulates Ca2+ release from RyR2
in cardiomyocytes. Prior studies have shown that JPH2 may be implicated in RyR2 stability.
Thus, we will investigate the molecular basis of JPH2 stabilizing RyR2 in cardiomyocyets.
On the other hand, oxidative damage to SERCA may also contribute to cytosolic Ca2+
overload in cardiomyocytes (182), which merits further investigation.
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